Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Acute flares before lung transplant put ILD patients at higher risk

Acute exacerbations, or sudden bouts of symptom worsening, increase the mortality risk after lung transplantation in people with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), a study reports. While a lung transplant is considered an effective treatment for ILDs, these findings “suggest that caution is required during decision-making,…

Pliant launches Phase 2b trial of oral bexotegrast in IPF

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…

CSP strikes $336M deal to market Daewoong’s IPF therapy in China

CS Pharmaceuticals (CSP) has entered into an exclusive in-licensing agreement with Daewoong Pharmaceutical to develop and commercialize bersiporocin, an oral experimental anti-fibrotic medication for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases in the greater China region. “This will be the stepping stone towards becoming a game…

RESP Biosensor Will Monitor Respiratory Issues at Home

Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…